Novo Nordisk A/S - Share repurchase programme
On 29 January 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 3.0 billion in the period from 29 January 2009 to 5
August 2009.
Since the announcement as of 27 April 2009, the following
transactions have been made under the programme:
Number of Average Transaction
shares purchase value,
price DKK
Accumulated, last
announcement 4,817,641 1,331,977,835
27 April 2009 90,000 270.18 24,316,200
28 April 2009 90,000 267.97 24,117,300
29 April 2009 90,000 270.08 24,307,290
30 April 2009 105,000 272.96 28,660,800
1 May 2009 75,000 271.80 20,385,000
Accumulated under
the programme 5,267,641 1,453,764,425
Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 30,430 B-shares in the
period from 27 April to 1 May. The shares in these transactions were
not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of
30,089,593 treasury shares, corresponding to 4.7% of the share
capital. The total amount of shares in the company is 634,000,000
including treasury shares.
The Annual General Meeting of Novo Nordisk A/S, which was held on 18
March 2009, approved a 2.2% reduction in the total share capital by
cancellation of 14,000,000 treasury B shares of DKK 1 at a nominal
value of DKK 14,000,000. After the legal implementation of the share
capital reduction, which is expected to take place after expiry of
the legal notice period in June 2009, Novo Nordisk's share capital
will amount to DKK 620,000,000 divided into an A share capital of DKK
107,487,200 and a B share capital of DKK 512,512,800. Taking into
account the expected cancellation Novo Nordisk would currently own
2.6% of such reduced share capital.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,000
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Mette Kruse Danielsen Mads Veggerby Lausten
Tel: (+45) 4442 3883 Tel: (+45) 4443 7919
mkd@novonordisk.com mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: 4442 4471
krop@novonordisk.com
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 26 / 2009
